CureDuchenne Ventures' $1M Investment in Entos Pharmaceuticals for Innovative Gene Therapy CureDuchenne Ventures has made a significant $1M investment in Entos Pharmaceuticals. This funding aims to advance the development of gene therapies for Duchenne muscular dystrophy.

CureDuchenne Ventures' $1M Investment in Entos Pharmaceuticals for Innovative Gene Therapy #USA #San_Antonio #CureDuchenne #Entos_Pharmaceuticals #Fusogenix_PLV